MedTrace Logo

Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics

NCT07684274 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 290

Last updated 2026-07-06

No results posted yet for this study

Summary

Study on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics features, to effectively distinguish myeloma patients from healthy individuals.

Conditions

  • Multiple Myeloma (MM)
  • Smoldering Multiple Myeloma (SMM)
  • MGUS

Sponsors & Collaborators

  • Nanjing Geneseeq Technology Inc.

    collaborator INDUSTRY

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-13
Primary Completion
2027-07-31
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07684274 on ClinicalTrials.gov